HTG Molecular Diagnostics and Daiichi Sankyo Complete Master Services Agreement
April 17 2017 - 7:30AM
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of
instruments, reagents and services for molecular profiling
applications, announced that it has entered into a master services
agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for
work to be performed in HTG’s VERI/O laboratory. The initial
project includes the development of a custom assay for the
detection of nearly 3,000 mRNA targets using the HTG EdgeSeq
technology.
When completed, the custom assay will be used to
generate data from formalin-fixed, paraffin-embedded (FFPE)
samples. Daiichi Sankyo plans to use these data to identify a tumor
profiling assay for future studies under the
agreement. Daiichi Sankyo also has engaged HTG to process
several hundred FFPE samples using the HTG EdgeSeq ALKPlus
Assay EU in a research use only mode for exploratory research on
new, potential therapeutic biomarkers.
“We appreciate the confidence Daiichi Sankyo has
shown in our HTG EdgeSeq technology and VERI/O laboratory by
entering into the master services agreement. We are excited to
support their important research objectives and the ultimate goal
of identifying diagnostic tests that better target therapies for
improved patient response,” stated TJ Johnson, President and Chief
Executive Officer of HTG. “Development work for the initial
project is already underway in our laboratory.”
About HTG:
Headquartered in Tucson, Arizona, the mission of
HTG Molecular Diagnostics (HTG) is to empower precision medicine at
the local level. In 2013 the company commercialized its first
instrument platform and a portfolio of RNA assays that leveraged
HTG's original proprietary nuclease protection chemistry.
Continuous improvement led to the 2014 launch of the company’s HTG
EdgeSeq product line, which automates sample and targeted library
preparation for next-generation sequencing. Additional information
is available at www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
about the anticipated benefits or outcomes of our agreement with
Daiichi Sankyo Company, Limited, the capabilities of our
technology, and our ability to successfully develop custom assays
or develop, market and commercialize companion diagnostic assays.
Words such as "believes," "anticipates," "plans," "expects,"
"intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements, though not all
forward-looking statements necessarily contain these identifying
words. These forward-looking statements are based upon management's
current expectations, are subject to known and unknown risks, and
involve assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties,
including, without limitation, risks associated with the process of
developing, marketing and commercializing our products, our ability
to achieve and sustain sufficient market acceptance, and the
capabilities of our product and service solutions to keep pace with
rapidly changing technology and customer requirements. These and
other factors are described in greater detail in our filings with
the Securities and Exchange Commission, including without
limitation our Annual Report on Form 10-K for the year ended
December 31, 2016. All forward-looking statements contained in this
press release speak only as of the date on which they were made,
and we undertake no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Contact:
Westwicke Partners
Jamar Ismail
Phone: 415-513-1282
Email: jamar.ismail@westwicke.com
TJ Johnson
President / CEO
HTG Molecular Diagnostics
Phone: 520-547-2827 x130
Email: tjjohnson@htgmolecular.com
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From Apr 2024 to May 2024
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From May 2023 to May 2024